CPRX(Delisted)
Stock Fundamental
Valuation6.2/10
NeutralKey Valuation Metric
PE Method: CPRX's market cap is approximately 3.85B with TTM earnings of 22.13B, corresponding to a PE ratio of 17.4. Compared to the Biotechnology industry average, this valuation may be reasonable.
PS Method: CPRX's market cap is approximately 3.85B with a PS ratio of 6.5. Compared to the Biotechnology industry average, this valuation may be reasonable.
PEG Method: With a PE of 17.4 and forward PE of 17.4, the PEG ratio comes to 1.00, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that CPRX's P/E reached a peak of about 38.43 on 2024-11-04, and a trough of about 10.78 on 2023-09-29. The current P/E is 17.42, which places it at approximately the 24% percentile of its historical range, indicating a relatively reasonable valuation.
Share Price vs Future Cash Flow Value
CPRX's current stock price is about $31.49, while its Discounted Cash Flow valuation is about $28.05. Based on the Discounted Cash Flow model, the market price represents a price close to its intrinsic value.
Future Growth4.7/10
NeutralEarnings and Revenue Growth Forecasts
CPRX's Revenue moved from about 122.71M (2024) to about 149.39M (2026) in recent actuals. Analyst forecasts include about 163.14M, 167.08M, and 171.02M for the next forecast periods, implying an overall 3-year CAGR of roughly 4.6% versus the latest actual—indicating a fluctuating trend in Revenue..
Future Return on Equity
Analysts predict CPRX's future return on equity (Future ROE) will be about 8.1% over the next three years, higher than the Biotechnology industry average of -86.2%, indicating its leading position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance6.2/10
NeutralRevenue & Expenses Breakdown
CPRX's revenue primarily comes from Product Revenue, Net, License and Other, — and —. Among these, Product Revenue, Net accounts for 100.0%; License and Other for 0.0%, — for 0.0% and — for 0.0%. The company's main business is relatively concentrated.
Earnings & Revenue
- Earnings per share (TTM)—
- Gross margin90.31%
- Net profit margin42.66%
- Debt / equity—
Free Cash Flow vs Earnings Analysis
No FCF bridge data
Financial Health6.0/10
NeutralDebt to Equity History and Analysis
No financial health series
Balance Sheet
Assets
Liabilities + Equity
Dividends4.0/10
NeutralStability and Growth of Payments
No dividend stability data
Dividend Yield vs Market
CPRX's current dividend yield is 0.00%, while the Biotechnology industry average is around 1.96%. The top 25% of companies in the entire US market have a dividend yield of 2.67%, while the bottom 25% have a yield of 1.50%. In comparison, CPRX is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: CPRX is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: CPRX is not paying a notable dividend for the US market.
- Based on a composite score of 5.83/10, we rate CPRX as a Netural. Our analysis breaks down into 2.68/10 for Fundamentals, 4.57/10 for Technicals, and 6.61/10 for Sentiment, indicating the stock is likely to consolidate sideways.
- Based on a composite score of 5.83/10, we rate CPRX as a Netural. Our analysis breaks down into 2.68/10 for Fundamentals, 4.57/10 for Technicals, and 6.61/10 for Sentiment, indicating the stock is likely to consolidate sideways.
